The story of the erectile dysfunction drug presents a challenging picture for those considering investment. While the initial launch generated significant returns, the expiration of its patent opened the door to generic versions, dramatically eroding market share. This creates a unique risk for firms banking on similar blockbuster offerings, sug… Read More